Therapeutic Strategies to Optimize the Efficacy of Nicotine Replacement Therapies

REFERENCES

• CDC. Deaths from Chronic Obstructive Pulmonary Disease. United States, 2000–2005. MMWR 2008; 57: 1229–1232
   PubMedGoogle Scholar
• CDC. Annual smoking-attributable mortality, years of potential life lost, and productivity losses. United States, 1997–2001. MMWR 2005; 54: 625–8
   PubMedGoogle Scholar
• Willemse B WM, Postma D S, Timens W, ten Hacken N HT. The impact of smoking cessation on respiratory symptoms, lung function, airway hyperresponsiveness and inflammation. Eur Resp J 2005; 23: 464–76
   Web of Science ®Google Scholar
• Godtfredsen N S, Lam T H, Hansel T T, Leon M E, Gray N, Dresler C, Burns D M, Prescott E, Vestbo J. COPD-related morbidity and mortality after smoking cessation: status of the evidence. Eur Resp J 2008; 32: 844–53
   PubMed Web of Science ®Google Scholar
• Anthonisen N R, Connett J E, Murray R P. Smoking and lung function of Lung Health Study participants after 11 years. Am J Respir Crit Care Med 2002; 166: 675–9
   PubMed Web of Science ®Google Scholar
• Murray R P, Connett J E, Rand C S, Pan W, Anthonisen N R. Persistence of the effect of the Lung Health Study (LHS) smoking intervention over eleven years. Prev Med. 2002; 35: 314–9
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services, Public Health Service. Clinical Practice Guideline. May, 2008, http://www.surgeongeneral.gov/tobacco/treating_tobacco_use08.pdf Treating Tobacco Use and Dependence: 2008 Update
   Google Scholar
• Hughes J R, Stead L F, Lancaster T. Antidepressants for smoking cessation (Review), http://www.thecochranelibrary.com The Cochrane Library, 2007, Issue 4
   Google Scholar
• Tashkin D P, Kanner R, Bailey W, Buist S, Anderson P, Nides M A, Gonzales D, Dozier G, Patel M K, Jamerson B D. Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. Lancet 2001; 357: 1571–5
   PubMed Web of Science ®Google Scholar
• Wagena E J, van der 1Meer R M, Ostelo R J, Jacobs J E, van Schayck C P. The efficacy of smoking cessation strategies in people with chronic obstructive pulmonary disease: results from a systematic review. Respir Med. 2004; 98: 805–15
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Smoking Cessation in Subjects With Mild-to-Moderate Chronic Obstructive Pulmonary Disease (COPD). ClinicalTrials.gov Identifier: NCT00285012. Accessed on November 24, 2008
   Google Scholar
• Wagena E J, Knipschild P G, Huibers M JH, Wouters E FM, van Schayck C P. Efficacy of Bupropion and Nortriptyline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease. Arch Intern Med. 2005; 165: 2286–92
   PubMed Web of Science ®Google Scholar
• Anthonisen N R, Connett J E, Kiley J P, Altose M D, Bailey W C, Buist A S, Conway W A, Jr, Enright P L, Kanner R E, O'Hara P, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 1994; 272: 1497–505
   PubMed Web of Science ®Google Scholar
• Tønnesen P, Kim Mikkelsen K, Bremann L. Nurse-conducted smoking cessation in patients with COPD using nicotine sublingual tablets and behavioral support. Chest 2006; 130: 334–42
   PubMed Web of Science ®Google Scholar
• Wagena E J, Zeegers M PA, van Schayck C P, Wouters E FM. Benefits and risks of pharmacological smoking cessation therapies in chronic obstructive pulmonary disease. Drug Safety 2003; 26: 381–403
   PubMed Web of Science ®Google Scholar
• Jimenez-Ruiz C A, Masa F, Miravitlles M, Gabriel R, Viejo J L, Villasante C, Sobradillo V. Smoking characteristics: differences in attitudes and dependence between healthy smokers and smokers with COPD. Chest 2001; 119: 1365–70
   PubMed Web of Science ®Google Scholar
• Centre for Evidence Based Medicine, Oxford Centre for Evidence-based Medicine. May, 2001, www.cebm.net Levels of Evidence
   Google Scholar
• Stead L F, Perera R, Bullen C, Mant D, Lancaster T. Nicotine replacement therapy for smoking cessation (Review). The Cochrane Library 2008, http://www.thecochranelibrary.com Issue 4
   Google Scholar
• Tønnesen P, Paoletti P, Gustavsson G, Russell M A, Saracci R, Gulsvik A, Rijcken B, Sawe U. Higher dosage nicotine patches increase one-year smoking cessation rates: results from the European CEASE trial. Collaborative European Anti-Smoking Evaluation. European Respiratory Society. Eur Respir J 1999; 13: 238–46
   PubMed Web of Science ®Google Scholar
• Shiffman S, Ferguson S G. Nicotine patch therapy prior to quitting smoking: a meta-analysis. Addiction 2008; 103: 557–63
   PubMed Web of Science ®Google Scholar
• Schuurmans M M, van Diacon A HBX, Bolliger C. Effect of pre-treatment with nicotine patch on withdrawal symptoms and abstinence rates in smokers subsequently quitting with the nicotine patch: a randomized controlled trial. Addiction 2004; 99: 634–40
   PubMed Web of Science ®Google Scholar
• Rose J E, Behm F M, Westman E C, Kukovich P. Precessation treatment with nicotine skin patch facilitates smoking cessation. Nicotine Tob Res 2006; 8: 89–101
   PubMed Web of Science ®Google Scholar
• Jorenby D E, Leischow S J, Nides M A, Rennard S I, Johnston J A, Hughes A R, Smith S S, Muramoto M L, Daughton D M, Doan K, Fiore M C, Baker T B. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. New Engl J Med 1999; 340: 685–691
   PubMed Web of Science ®Google Scholar
• Aveyard P, Johnson C, Fillingham S, Parsons A, Murphy M. Nortriptyline plus nicotine replacement versus placebo plus nicotine replacement for smoking cessation: pragmatic randomised controlled trial. BMJ 2008; 336(7655)1223–1227
   PubMed Web of Science ®Google Scholar
• http://www.pfizer.com/files/products/uspichantix.pdf Accessed on December 1, 2008
   Google Scholar
• van d er, Meer R M, Wagena E J, Ostelo R WJG, Jacobs J E, van Schayck C P. Smoking cessation for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2001, Issue 1. Art. No.: CD002999. DOI: 10.1002/14651858. CD002999
   Google Scholar
• Murray R P, Nides M A, Istvan J A, Daniels K. Levels of cotinine associated with long-term ad-libitum nicotine polacrilex use in a clinical trial. Addict Behav 1998; 23: 529–535
   PubMed Web of Science ®Google Scholar
• Medioni J, Berlin I, Mallet A. Increased risk of relapse after stopping nicotine replacement therapies: a mathematical modelling approach. Addiction. 2005; 100: 247–254
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Adjustment of DOses of NIcotine in Smoking Cessation (ADONIS). ClinicalTrials.gov Identifier: NCT00235313. Accessed on December 1, 2008
   Google Scholar